FindTrial
Sign In

Efficacy and Safety of Dabigatran for Thromboprophylaxis after Total Knee or Hip Arthroplasty : a pilot study

Efficacy and Safety of Dabigatran for Thromboprophylaxis after Total Knee or Hip Arthroplasty : a pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20150504001
Enrollment
Unknown
Registered
2015-05-04
Start date
2015-05-05
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary knee or hip arthroplasty TKA&#44

Interventions

Dabigatran for thromboprophylaxis,no treatment
Active Comparator Drug,Placebo Comparator No treatment
Dabigatran group,Control group

Sponsors

Golden Jubilee Medical Center
Lead Sponsor
Golden Jubilee Medical Center
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: � primary TKA or THA � blood loss less than 1,200 cc. � age between 18 - 90 year � preoperative doppler u/s screennig normal

Exclusion criteria

Exclusion criteria: abnormal bleeding history abnormal liver function test eGFR < 30 mm/min previous DVT

Design outcomes

Primary

MeasureTime frame
thromboembolic evet 6 to 10 day after surgery doppler ultrasound,major bleeding complication 3 and 7 days after surgery hematoma grading scale—

Secondary

MeasureTime frame
blood loss&#44; minor bleeding complication&#44; blood transfusion 3 and 7 days after surgery ml&#44; unit—

Countries

Thailand

Contacts

Public ContactTawan Intiyanaravut

Golden Jubilee Medical Center

tawan.int@mahidol.ac.th0894476068

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026